Erratum to: Pharmaceutical cost management in an ambulatory setting using a risk adjustment tool
| Autor: | Carla Sancho-Mestre, Ruth Usó-Talamantes, Laia Buigues-Pastor, José Luis Trillo-Mata, Natividad Guadalajara-Olmeda, David Vivas-Consuelo |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Cost Control Cost accounting Health informatics Drug Costs Health administration Pharmaceutical expenditure Predictive models 03 medical and health sciences 0302 clinical medicine Health care medicine Ambulatory Care Humans 030212 general & internal medicine Health policy Chronic condition business.industry 030503 health policy & services Nursing research lcsh:Public aspects of medicine Health Policy Clinical Risk Groups Capitation payments lcsh:RA1-1270 Risk adjustment medicine.disease Cross-Sectional Studies Models Economic Spain Ambulatory Emergency medicine Female Medical emergency Erratum 0305 other medical science business Research Article |
| Zdroj: | BMC Health Services Research BMC Health Services Research, Vol 17, Iss 1, Pp 1-1 (2017) |
| ISSN: | 1472-6963 |
| Popis: | Background Pharmaceutical expenditure is undergoing very high growth, and accounts for 30% of overall healthcare expenditure in Spain. In this paper we present a prediction model for primary health care pharmaceutical expenditure based on Clinical Risk Groups (CRG), a system that classifies individuals into mutually exclusive categories and assigns each person to a severity level if s/he has a chronic health condition. This model may be used to draw up budgets and control health spending. Methods Descriptive study, cross-sectional. The study used a database of 4,700,000 population, with the following information: age, gender, assigned CRG group, chronic conditions and pharmaceutical expenditure. The predictive model for pharmaceutical expenditure was developed using CRG with 9 core groups and estimated by means of ordinary least squares (OLS). The weights obtained in the regression model were used to establish a case mix system to assign a prospective budget to health districts. Results The risk adjustment tool proved to have an acceptable level of prediction (R2 ≥ 0.55) to explain pharmaceutical expenditure. Significant differences were observed between the predictive budget using the model developed and real spending in some health districts. For evaluation of pharmaceutical spending of pediatricians, other models have to be established. Conclusion The model is a valid tool to implement rational measures of cost containment in pharmaceutical expenditure, though it requires specific weights to adjust and forecast budgets. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink